Dr Daniel Whiten
High tech project offers hope for Parkinson’s treatment Kolling researchers are set to lead a ground-breaking project to identify new drug therapies for those with Parkinson’s disease. will help our team translate our scientific progress into an effective treatment for Parkinson’s disease patients.
but we have identified a new pathway to restore cellular function in the brain, and this project will help us identify the compounds which can activate this pathway and reduce the impact of Parkinson’s disease. “The funding means we will now have access to highly specialised robotic screening at the Walter and Eliza Hall Institute, allowing us to test several hundred thousand compounds in a relatively short amount of time.
“Parkinson’s disease affects approximately one per cent of the population over 65, leading to a continual loss of neurons in the brain, and loss of function,” he said. “Currently, we are unable to slow or stop this process with medication,
The project has been made possible following Federal Government funding through the National Drug Discovery Centre. Senior Kolling researcher Dr Daniel Whiten has welcomed the announcement, saying the funding
6
KOLLINGNEWS | MAY 2021
Made with FlippingBook - professional solution for displaying marketing and sales documents online